Highlights from the 2025 Annual General Meeting of SciBase Holding AB

On June 17, 2025, SciBase Holding AB held its annual general meeting, outlining vital decisions that will shape the company's future. The meeting proved to be a significant event for stakeholders, as it laid out resolutions related to financial performance and governance.

Key Resolutions Passed

The attendees of the meeting reviewed the financial results for 2024, adopting both the profit and loss statement and the balance sheet for the fiscal year. Notably, the company has decided not to distribute any dividends for this period, choosing instead to carry the earnings into future growth plans. This reflects a focus on maximizing reinvestment into the business rather than immediate shareholder returns.

Furthermore, the board was granted discharge from liability regarding its decisions for the 2024 fiscal year. This step ensures that board members can operate with confidence, knowing they are protected from potential repercussions as they navigate the complexities of corporate governance.

Board Composition Changes

A major development during the meeting was the re-election of current executive members, along with the elevation of Anna Eriksrud to the board. With a board now consisting of four ordinary members, this streamlined decision-making body aims to enhance strategic oversight. Jesper Høiland was re-elected to serve as the board chairman, ensuring continuity in leadership for future initiatives.

Compensation for Board Members
The meeting specified that the board of directors will receive fees amounting to SEK 404,000 for its chairman and SEK 135,000 for other board members. Such compensation is vital for attracting and retaining talented individuals who guide SciBase towards innovative ventures.

Audit and Accountability Measures

The auditing responsibilities of the company will now be handled by Öhrlings PricewaterhouseCoopers AB, with Magnus Lagerberg designated as the auditor in charge. This decision reflects SciBase’s commitment to transparency and accountability, ensuring rigorous financial oversight as it pursues growth.

Incentive Programs and Share Capital Adjustments

In addition to the board updates, the meeting unveiled plans for an incentive program that would involve the issuance of warrants. Such measures are crucial for aligning the interests of stakeholders and fostering an environment of shared success.

The company also amended its articles of incorporation to adjust its share capital parameters. With a new minimum share capital established at SEK 16,914,781.65 and a maximum of SEK 67,659,126.60, SciBase is positioned for significant expansion. The current share structure allows for the potential issuance of additional shares, convertible debentures, or warrants, aimed at supporting financially advantageous decisions that may dilute current shareholder stakes up to 30%.

Future Outlook

As SciBase moves forward, there is a clear focus on innovation within the dermatological field, particularly with its digital health solutions such as Nevisense. This annual meeting illustrates the company's commitment not only to its financial health but also to improving patient outcomes through advanced medical technology. With over 20 years of research backing its initiatives, SciBase stands as a frontrunner in skin health diagnostics.

For more information about the company’s governance and operations, stakeholders are encouraged to visit SciBase's website. Here, one can find an array of resources, including the annual meetings and strategic documents that outline the company's trajectory.

This year's annual meeting reaffirmed SciBase's commitment to advancing technology in healthcare while prioritizing shareholder interests and corporate responsibility. As a publicly traded company listed on the Nasdaq First North Growth Market, SciBase continues its journey towards leading the charge in innovative dermatological solutions.